收费全文 | 4036篇 |
免费 | 240篇 |
国内免费 | 15篇 |
耳鼻咽喉 | 22篇 |
儿科学 | 130篇 |
妇产科学 | 38篇 |
基础医学 | 488篇 |
口腔科学 | 51篇 |
临床医学 | 384篇 |
内科学 | 1066篇 |
皮肤病学 | 62篇 |
神经病学 | 459篇 |
特种医学 | 173篇 |
外科学 | 582篇 |
综合类 | 11篇 |
预防医学 | 258篇 |
眼科学 | 87篇 |
药学 | 242篇 |
中国医学 | 1篇 |
肿瘤学 | 237篇 |
2024年 | 3篇 |
2023年 | 31篇 |
2022年 | 42篇 |
2021年 | 135篇 |
2020年 | 88篇 |
2019年 | 118篇 |
2018年 | 129篇 |
2017年 | 111篇 |
2016年 | 105篇 |
2015年 | 111篇 |
2014年 | 152篇 |
2013年 | 233篇 |
2012年 | 366篇 |
2011年 | 363篇 |
2010年 | 188篇 |
2009年 | 192篇 |
2008年 | 262篇 |
2007年 | 275篇 |
2006年 | 285篇 |
2005年 | 242篇 |
2004年 | 221篇 |
2003年 | 200篇 |
2002年 | 163篇 |
2001年 | 33篇 |
2000年 | 27篇 |
1999年 | 29篇 |
1998年 | 23篇 |
1997年 | 30篇 |
1996年 | 19篇 |
1995年 | 21篇 |
1994年 | 13篇 |
1993年 | 14篇 |
1992年 | 9篇 |
1991年 | 7篇 |
1990年 | 6篇 |
1989年 | 6篇 |
1988年 | 3篇 |
1987年 | 3篇 |
1986年 | 5篇 |
1985年 | 3篇 |
1984年 | 5篇 |
1983年 | 5篇 |
1982年 | 3篇 |
1981年 | 4篇 |
1977年 | 1篇 |
1975年 | 1篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1964年 | 1篇 |
1961年 | 1篇 |
Background
In previous studies, correlation between overall survival (OS) and surrogate endpoints like objective response rate (ORR) or progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) was poor. This can be biased by crossover and postprogression treatments.Objectives
To evaluate the relationship between these two surrogate endpoints and OS in advanced NSCLC studies that did not allow for crossover or reported balanced post-progression treatments.Methods
A systematic review in patients with advanced NSCLC receiving second- and further-line therapy was performed. The relationship between the absolute difference in ORR or median PFS (mPFS) and the absolute difference in median OS (mOS) was assessed using the correlation coefficient (R) and weighted regression models. The analysis was repeated in predefined data cuts based on crossover and balance of postprogression treatments. When the upper limit of R’s 95% confidence interval (CI) was more than 0.7, the surrogate threshold effect (STE) was estimated.Results
In total, 146 randomized clinical trials (43,061 patients) were included. The mean ORR, mPFS, and mOS were 12.2% ± 11.2%, 3.2 ± 1.3 months, and 9.6 ± 4.1 months, respectively. The correlation coefficients of ORR and mPFS were 0.181 (95% CI 0.016–0.337) and 0.254 (95% CI 0.074–0.418), respectively, with mOS. Nevertheless, in trials that did not allow crossover and reported balanced postprogression treatments, the correlation coefficients of ORR and mPFS were 0.528 (95% CI 0.081–0.798) and 0.778 (95% CI 0.475–0.916), respectively, with mOS. On the basis of STE estimation, in trials showing significant treatment effect size of 41.0% or more ORR or 4.15 or more mPFS months, OS benefit can be expected with sufficient certainty.Conclusions
Crossover and postprogression treatments may bias the relationship between surrogate endpoints and OS. Presented STE calculation can be used to interpret treatment effect on either ORR or PFS when used as primary endpoints. 相似文献Background
Lung cancer screening can reduce cancer mortality. Most implementation studies focus only on low-dose computed tomography (LDCT) and clinical attributes of screening and do not include preferences of potential participants. In this study we evaluated the perceived value of screening programs based on LDCT, breath analysis (BA), or blood biomarkers (BB) according to the perspective of the target population.Methods
A multi-criteria decision analysis framework was adopted. The weights of seven attributes of screening (sensitivity, specificity, radiation burden, duration of screening process, waiting time until results are communicated, location of screening, and mode of screening) were obtained from an earlier study that included a broad sample from the Netherlands. Performance data for the screening modalities was obtained from clinical trials and expert opinion. Parameter uncertainty about clinical performances was incorporated probabilistically, while heterogeneity in preferences was analyzed through subgroup analyses.Results
The mean overall values were 0.58 (CI: 0.57 to 0.59), 0.57 (CI: 0.56 to 0.59), and 0.44 (CI: 0.43 to 0.45) for BB, BA, and LDCT, respectively. Seventy-seven per cent of respondents preferred BB or BA. For most subgroups, the overall values were similar to those of the entire sample. BA had the highest value for respondents who would have been eligible for earlier screening trials.Discussion
BB and BA seem valuable to participants because they can be applied in a primary care setting. Although LDCT still seems preferable given its strong and positive evidence base, it is important to take non-clinical attributes into account to maximize attendance. 相似文献Methods: Eighteen models of craving were reviewed by applying a literature search with a five-step strategy that accounted for the momentary nature of craving and included a snowballing search and a key term extraction algorithm. Based on this review, multiple decision criteria were defined upon which to evaluate the models.
Results: Six models for alcohol craving were supported by sufficient empirical research to be eligible. The inferences drawn on these six models resulted in three decision criteria: the model should (1) incorporate negative affect as a predictor of relapse; (2) explain that dependent drinkers have a higher attentional bias towards alcohol cues than nondependent drinkers; (3) incorporate increased risk of relapse with heightened stress levels.
Conclusions: The affective processing model of negative reinforcement, the cognitive processing model, the incentive sensitization theory of addiction and the theory of neural opponent motivation are classified as viable theoretical frameworks, resulting in negative affect and stress as relevant parameters to include in real-time craving monitoring research. 相似文献